Zeolitic Imidazolate Framework Nanoencapsulation of CpG for Stabilization and Enhancement of Immunoadjuvancy

Olivia R. Brohlin, Ryanne N. Ehrman, Fabian C. Herbert, Yalini H. Wijesundara, Arun Raja, Arezoo Shahrivarkevishahi, Shashini D. Diwakara, Ronald A. Smaldone, and Jeremiah J. Gassensmith† *

Department of Chemistry and Biochemistry, The University of Texas at Dallas, 800 W. Campbell Road, Richardson, Texas 75080, United States

†Department of Biomedical Engineering, The University of Texas at Dallas, 800 W. Campbell Road, Richardson, Texas 75080, United States

*E-mail: gassensmith@utdallas.edu. Web: www.gassensmithlab.com

KEYWORDS
Metal-organic framework, zeolitic imidazolate framework 8, CpG, immunoadjuvant, phosphodiester DNA, B-cell activation, nuclease resistance

ABSTRACT
Metal organic frameworks (MOFs) have been used to improve vaccine formulations by stabilizing proteins and protecting them against thermal degradation. This has led to increased
immunogenicity of these proteinaceous therapeutics. In this work we show that MOFs can also be used to protect the ssDNA oligomer, CpG, to increase its immunoadjuvancy. By encapsulating phosphodiester CpG in the zinc-based MOF, ZIF-8, the DNA oligomer is protected from nuclease degradation and exhibits improved cellular uptake. As a result, we have been able to achieve drastically enhanced B-cell activation in splenocyte cultures comparable to the current state-of-the-art, phosphorothioate CpG. Furthermore, we have made a direct comparison of micro- and nano-sized MOF for the optimization of particulate delivery of immunoadjuvants to maximize immune activation.

INTRODUCTION

Metal organic frameworks (MOFs) have been used to stabilize a wide variety of biomacromolecules including proteins,1-2 viruses,3 and liposomes4 against thermal degradation as a means to overcome the “Cold Chain”. This technology has been revolutionary in overcoming the notorious instability of biological therapeutics and offers the possibility of significantly reducing their cost and increasing their accessibility – specifically in developing areas that lack the infrastructure to maintain the required refrigeration for storage and transport.5-6 These powerful polymeric frameworks are formed through coordination bonds between a metal node and organic linkers.7-9 Biomacromolecules act as nucleating agents that catalyze MOF formation, resulting in encapsulation through a process called biomimetic mineralization.10-13 Once encapsulated, the biomacromolecule is protected from enzymatic degradation14 and thermal denaturation.15-16 The resulting structure is thermodynamically stable17-19 but is kinetically labile and easily degrades in the presence of strong metal chelators,20-21 low pH,22-23 and inorganic phosphates24 that allows for the recovery of the preserved biomacromolecule. In this work, we
apply this technology for the encapsulation of the single stranded DNA (ssDNA) immunoadjuvant, CpG.

Vaccines often have a limited ability to activate the B- and T-cell mediated components of the immune system and therefore must be combined with an immunoadjuvant to promote and direct the immune response.\textsuperscript{25-27} Synthetic adjuvants designed to mimic pathogen-associated molecular patterns (PAMPs) can bind to pattern recognition receptors (PRRs) to begin the process of switching immune cells from a passive naïve state to an active state ready to fight infection.\textsuperscript{28-29} CpG is a synthetic immunoadjuvant composed of single stranded, unmethylated, bacterial DNA.\textsuperscript{30-31} In mammals, 70-80\% of CpG cytosines are methylated, therefore unmethylated CpG is recognized by the immune system as a PAMP.\textsuperscript{32-33} The immunoadjuvant, CpG, can activate both plasmacytoid dendritic cells (pDCs) and B-cells to trigger a proinflammatory response.\textsuperscript{34} This is important as pDCs are the body’s vanguards against infection by foreign pathogens and proliferation of cancer while B-cells are responsible for producing different types of proteins that bind to and neutralize infection – in particular different types of immunoglobulins or antibodies.

There are two main types of CpG, each specializing in activating a specific part of the innate immune system. Class A CpG (also referred to as D-type) more strongly activates pDCs and promotes a T cell mediated cellular immune response;\textsuperscript{35} whereas, class B CpG (K-type) more strongly activates B-cells and promotes a humoral immune response.\textsuperscript{36} Due to it’s ability to boost antibody production, class B CpG immunoadjuvants have been the focus of human clinical trials for vaccines, infectious diseases, and cancer.\textsuperscript{37-39} The major limitation undermining the success of CpG in clinical trials comes from the nuclease susceptibility of the DNA backbone.\textsuperscript{40} The current state-of-the-art technology has reengineered the labile phosphodiester (PO)
backbone by thiolation of the sugar moiety to form a nuclease-resistant phosphorothioate (PS) bond, resulting in an increased \textit{in vivo} half-life of 30–60 min (5–10 min for PO).\textsuperscript{41} However, this modification has been found to lower the immunoadjuvancy of CpG and induce acute toxicity.\textsuperscript{42-43}

As an alternative to the PS backbone modification, we propose using MOFs to improve the \textit{in vivo} stability of PO CpG. In this way, we can protect CpG from nucleases while also retaining the innate immunoadjuvancy of the oligonucleotide. Recent work with zeolitic imidazolate framework-8 (ZIF-8), a zinc-based MOF, has shown it possible to grow a MOF shell around biomacromolecules in a simple one-pot synthesis under ambient conditions.\textsuperscript{44-47} The resulting formulation does not require refrigeration, unlike other currently used nanocarriers such as lipid nanoparticles,\textsuperscript{48} virus-like particles,\textsuperscript{49} and liposomes.\textsuperscript{50} ZIF-8 forms a protective barrier that inhibits enzymatic degradation of biomacromolecules.\textsuperscript{51} ZIF-8 has previously served\textsuperscript{52} as a nanoparticle carrier of PS CpG by electrostatically binding the negatively charged CpG onto the cationic surface of the crystals to promote cellular uptake and enhance immunoadjuvancy in macrophages. In this work, we encapsulate PO CpG within ZIF-8 to protect the DNA from nucleases and enhance immunoadjuvancy by improving B-cell activation (\textbf{Scheme 1}). Furthermore, we have optimized our formulation by tuning the ZIF-8 metal-to-ligand ratios to synthesize both micro- and nano-sized CpG@ZIF.
**Scheme 1.** Illustration of the encapsulation of CpG in ZIF-8 for enhanced immunoadjuvancy.

The ssDNA immunoadjuvant, CpG, is encapsulated in the zinc-based MOF, ZIF-8, by biomimetic mineralization using Zn\(^{2+}\) and 2-methylimidazole. Encapsulation of CpG within ZIF-8 affords nucleic acid protection from nucleases and promotes cellular uptake for enhanced B-cell activation.

**EXPERIMENTAL**

**Materials**

PO CpG (ODN 1826-Class B) and FITC-labeled PO CpG were purchased as a custom DNA oligomer from Invitrogen (sequence: 5’-tccatgacgttcctgacgtt-3’ (20 mer); 5’ FAM modification). PS CpG (ODN 1826), FITC-labeled PS CpG (ODN 1826 FITC), and PS GpC (ODN 1826 control: ODN 2138) were purchased from Invivogen. Nuclease-free water, zinc acetate dihydrate, 2-methylimidazole, β-mercaptoethanol, RPMI-1640, Dulbecco's Modified Eagle Medium, FB Essence, penicillin-streptomycin, phosphate buffered saline, and Desoxyribonuclease I (DNase I) were purchased from Sigma-Aldrich (St. Louis, MO, USA), Thermo Fisher Scientific (Waltham, MA, USA), or VWR (Radnor, PA, USA). LDH-Cytox assay kit, cell staining buffer, RBC lysis buffer, Alexa Fluor® 700 anti-mouse CD19 Antibody, Alexa Fluor® 647 anti-mouse CD80 Antibody, and PE anti-mouse CD86 Antibody were purchased from Biolegend.

**CpG@ZIF Synthesis and Characterization**

*Synthesis of CpG@ZIF*
Stock solutions of 1 M Zn(OAc)$_2$ and 3 M 2-methylimidazole (HMIM) were made in nuclease-free water. For the synthesis of the CpG@µZIF, 213 µL of 3 M HMIM (final concentration 640 mM) was combined with 708 µL of nuclease-free water. 39 µL of 100 µM PO CpG (final concentration 25 µg/mL) was added and the solution was vortexed for 10 s. Lastly, 40 µL of 1 M Zn(OAc)$_2$ (final concentration 40 mM) was added and the solution was vortexed for another 30 s. The solution immediately turned turbid and was allowed to react at RT for 1 h. The same was done for the synthesis of CpG@nZIF using 853 µL of 3 M HMIM (final concentration 2560 mM), 28 µL nuclease-free water, 39 µL of 100 µM PO CpG (final concentration 25 µg/mL), and 80 µL 1 M Zn(OAc)$_2$ (final concentration 80 mM). For the synthesis of pristine ZIF, the same conditions were used except 39 µL of additional nuclease-free water was added in place of 39 µL of PO CpG. The resulting solutions were centrifuged at 17,000 x g for 10 mins to obtain a pellet of the crystals. The crystals were then washed with 1000 µL of methanol, 500 µL methanol and 500 µL nuclease-free water mixture, and 1000 µL nuclease-free water using the same centrifugation method. The final pellet was resuspended in nuclease-free water. The same procedure was used for the encapsulation of FITC-labeled CpG. For adsorption of CpG onto the surface of ZIF (CpG+ZIFs), 39 µL of 100 µM PO CpG was combined with pristine ZIF in a total reaction volume of 100 µl and incubated on a rotisserie for 1 h at RT. The samples were purified by centrifugation (17,000 x g for 10 mins) however no subsequent washings were employed to prevent dislodging the surface adsorbed CpG.

**Characterization of CpG@ZIF**

*SEM.* The surface morphology of the CpG@ZIFs was examined using a Zeiss Supra 40 scanning electron microscope at 2.5 kV and 6–10 mm working distance. 5 µL of the prepared crystals in nuclease free water were loaded onto a silicon wafer, allowed to dry for 10 s, and the excess
wicked off using Whatman Filter Paper #1. The samples were then sputtered with a ~40 Å layer of gold before being imaged.

**DLS.** The size and polydispersity of the CpG@ZIFs was quantified using a Malvern Analytical Zetasizer Nano ZS. 1 mL of the crystals diluted in nuclease-free water was loaded into a 1 mL disposable cuvette and read at 25 °C, a 175° scattering angle, a medium refractive index of 1.33, a 633 nm laser, and a material refractive index of 1.51.

**ζ Potential.** The charge of the CpG@ZIFs was quantified using a Malvern Analytical Zetasizer Nano ZS. 1 mL of the crystals diluted in nuclease-free water was loaded into a 1 mL disposable folded capillary cell and read at 25 °C.

**PXRD.** Crystallinity of the CpG@ZIFs was determined with a Rigaku SmartLab X-ray Diffractometer with CuKα (1.54060 Å) at 30 mA and 40 kV. The samples were washed with methanol and put under vacuum overnight before being analyzed.

**BET Nitrogen Isotherms.** The surface areas of the CpG@ZIFs were quantified using a Micrometrics ASAP 2020 surface area analyzer. Nitrogen adsorption measurements were taken at 77 K. Samples were activated in MeOH for 4 h, dried under vacuum for 24 h, soaked with DCM for 4 h, and finally dried under vacuum for another 24 h. Before analysis, the samples were put under vacuum and degassed at 120 °C for 12 h. The data was processed by Brunauer–Emmett–Teller (BET) method for calculation of the surface area and pore sizes quantified by a non-localized density functional theory (NLDFT) with a carbon slit pore model.

**Confocal Microscopy.** The fluorescence of the FITC-labeled PO CpG encapsulated in ZIF-8 was qualitatively observed using an Olympus FV3000 RS Confocal microscope. 10 µL of sample was loaded onto a glass slide, covered with a glass cover slip and left to dry overnight in the
dark. The slide was then sealed and imaged using 100 × magnification. Images were processed using ImageJ software.

Fluorimetry. The encapsulation efficiency of FITC-labeled PO CpG in ZIF-8 before and after denaturing washes was quantified by measuring the FITC fluorescence intensity of the supernatant during synthesis. For washing, CpG@ZIFs were either treated with 10% SDS for 30 mins at RT or 2 units of DNase I for 10 mins at 37 °C. After, the solution was centrifuged at 17,000 ×g for 10 mins and 100 µL of the supernatant was added to a black 96 well plate in triplicate. Fluorescence readings at λex = 495 nm; λem = 520 nm were performed on a BioTek Synergy H4 Hybrid Microplate Reader. The encapsulation efficiency was calculated as a percent of the FITC fluorescence intensity of the starting material.

CpG@ZIF Stability Against DNase I

The digestion was performed according to the manufacturer’s protocol. In brief, 10 µg of encapsulated and unencapsulated PO CpG (as well as PS CpG) were incubated with 1 µL (2 units) of DNase I and 10 µL of 10× DNase reaction buffer (final concentration 1×) in a final reaction volume of 100 µL using nuclease-free water. The mixture was incubated for 10 mins at 37 °C. The reaction was quenched with 1 µL of 0.5 M EDTA. The digested and undigested CpG@ZIFs samples were centrifuged at 17,000 ×g for 10 mins and the supernatants decanted. 100 µL of 0.5 M EDTA was used to dissolve the ZIF-8 crystals and recover the CpG. The recovered CpG samples were run on a 5% agarose gel containing 0.5 mg/mL ethidium bromide at 100 V for 10 mins with 1× TBE running buffer alongside a ultra low range DNA ladder. The same was done for adsorbed samples (CpG+ZIFs) except EDTA exfoliation was not required to recover the CpG.
CpG@ZIF Performance In Vitro

Cytotoxicity

The cell viability assay was performed according to the manufacturer’s protocol. In brief, RAW 264.7 murine macrophages were grown in DMEM supplemented with 10% FB Essence and 1% penicillin-streptomycin. The cells were then seeded at a concentration of $1 \times 10^6$ cells/mL in a 96 well plate (100 μL/well) and allowed to adhere overnight. All incubations took place in a 37 °C CO$_2$ incubator. The following day the cells were treated with the CpGs, CpG@ZIFs, or ZIFs at a CpG concentration of 3.3 μg/mL (100 μL/well) for 4 h. Next, 10 μL of lysis buffer was added to a set of untreated cells for 30 mins to create the negative control. After, 100 μL of working solution was added to all of the wells for 30 mins in a light protected area. Lastly, 50 μL of stop solution was added to all wells before reading the absorbance at 490 nm on a BioTek Synergy H4 Hybrid Microplate Reader.

Uptake

Spleens from naïve BALB/c mice were collected from euthanized mice in accordance with protocol #19-06 approved by the University of Texas at Dallas Institutional Animal Care and Use Committee (IACUC). Spleens were homogenized into single cell suspensions using cell pestles and 100 μm cell strainers and red blood cells were lysed with 1× RBC lysis buffer. Splenocytes were seeded at $1 \times 10^6$ cells/mL in a 24 well plate (2 mL/well). The splenocytes were treated with FITC-labeled CpGs, CpG@ZIFs, or ZIFs (3.3 μg/mL CpG concentration) in RPMI supplemented with 10% FB Essence, 1% penicillin-streptomycin, and 50 μM β-mercaptoethanol for 4 h at 37 °C in a CO$_2$ incubator. After, the cells were washed 3× with 0.5 M sodium acetate buffer pH 5 to remove surface bound material, washed 3× with 1× PBS, stained
with Alexa Fluor® 700 anti-mouse CD19 Antibody to identify B cells, washed 3× with cell staining buffer, and finally resuspended in 1 mL of cell staining buffer. Quantitative analyses were completed using a BD LSR Fortessa flow cytometer with approximately 100,000 events collected per sample. Data processing was performed on FlowJo software Version 10.6.1.

**B-cell Activation**

Spleens from naïve BALB/c mice were collected from euthanized mice in accordance with protocol #19-06 approved by the University of Texas at Dallas Institutional Animal Care and Use Committee (IACUC). Spleens were homogenized into single cell suspensions using cell pestles and 100 μm cell strainers and red blood cells were lysed with 1× RBC lysis buffer. Splenocytes were seeded at 1 × 10⁶ cells/mL in a 24 well plate (2 mL/well). The splenocytes were treated with FITC-labeled CpGs, CpG@ZIFs, or ZIFs (3.3 μg/mL CpG concentration) in RPMI supplemented with 10% FB Essence, 1% penicillin-streptomycin, and 50 μM β-mercaptoethanol for 4 h at 37 °C in a CO₂ incubator. The cells were washed 3× with 0.5 M sodium acetate buffer at pH 5 to remove surface bound material, washed 3× with 1× PBS, stained with Alexa Fluor® 700 anti-mouse CD19 Antibody, Alexa Fluor® 647 anti-mouse CD80 Antibody, and PE anti-mouse CD86 Antibody to identify activated B cells, washed 3× with cell staining buffer, and finally resuspended in 1 mL of cell staining buffer. Quantitative analyses were completed using a BD LSR Fortessa flow cytometer with approximately 100,000 events collected per sample. Data processing was performed on FlowJo software Version 10.6.1.

**RESULTS AND DISCUSSION**

Biomimetic mineralization of ZIF-8 on the surface of CpG was done by iteratively adjusting aqueous solutions of zinc acetate and 2-methylimidazole (HMIM) as the metal node
and organic ligand, respectively. Tuning the metal-to-ligand ratio allows us to not only capture the oligonucleotide, but also control the size of the ZIF-8. From our initial screen we found that we could produce CpG encapsulated in micro-sized crystals (CpG@µZIF) when we used 40 mM Zn(OAc)$_2$, 640 mM HMIM, and 25 µg/mL CpG. Further, we found that when we used 80 mM Zn(OAc)$_2$, 2560 mM HMIM, and 25 µg/mL CpG we could synthesize nano-sized crystals (CpG@nZIF). Prior work using time-resolved X-ray spectroscopy shows ZIF-8 formation begins within seconds; consequently, the time the DNA resides at these high concentrations of metals and ligand is extremely short before it becomes encapsulated. SEM micrographs of the resulting micro (Figure 1A) and nano (Figure 1B) crystals show the characteristic rhombic dodecahedral shape of ZIF-8 that are consistent with pristine ZIFs (Figure 1C&D). Furthermore, the crystallinity of the CpG@ZIFs was measured by PXRD with the patterns matching that of pristine and simulated ZIF-8 (Figure 1E). Following activation, we found the resulting composites were still porous. As expected, the nitrogen isotherms of the CpG@µZIF and CpG@nZIF show diminished surface areas, which is attributed to the presence of CpG in the ZIF-8 (Figure 1F). The hydrodynamic radius of the resulting composites was measured via dynamic light scattering (DLS). From these data we found CpG@µZIF to have a size around ~1.3 µm (PDI: 0.374) whereas CpG@nZIF was ~215 nm (PDI: 0.470) (Figure 1G). The ability to control the size of the composites is important in the formulation of vaccines and adjuvants. Polymeric vaccine formulations often advocate for a larger particle size ranging from 500 nm to several microns with the advantage of providing a sustained release system. With these constructs, we have seen a heightened humoral immune response and prolonged immunity, however, literature reports that particles should be less than 500 nm for optimal uptake by immune cells. Having two sizes of CpG@ZIF both above and below this cut off allows us to
make a direct comparison of micro- and nano-size MOFs for optimal delivery of CpG and subsequent activation of B-cells. Further characterization of both micro and nano formulations found that encapsulation of the CpG in ZIF-8 resulted in a slight shielding of the strong negative charge of the DNA by the positively charged MOF (Figure 1H). It was hypothesized that this factor may also play an important role in mediating cell uptake as mammalian cell membranes are negatively charged owing to the presence of phosphatidyl serine and thus cargo with strong negative charges are thought to be electrostatically repelled from cell surfaces.\textsuperscript{56-57}

![Figure 1](image.png)

**Figure 1.** Encapsulation of CpG and in micro and nano ZIF-8. A) SEM micrograph of CpG@\(\mu\)ZIF. B) SEM micrograph of CpG@nZIF. C) SEM micrograph of pristine \(\mu\)ZIF. D) SEM
micrograph of pristine nZIF. E) PXRD patterns of CpG@µZIF and CpG@nZIF as compared to pristine and simulated ZIF-8. F) Brunauer–Emmett–Teller nitrogen isotherms assessing the reduction in surface area as a result of CpG encapsulation in µZIF and nZIF. G) DLS characterization of the size distribution of CpG@µZIF and CpG@nZIF. H) ζ-potential measurements illustrating the reduction in negative charge of CpG after encapsulation in the positively charged ZIFs.

To quantitatively and qualitatively confirm DNA encapsulation within ZIF, fluorescently-labeled CpG, FITC-CpG, was used. The encapsulation efficiency was first quantified by measuring the amount of unencapsulated material in the supernatant during synthesis. Fluorometric analyses shows that CpG was encapsulated quantitatively (~95%; 23-24 µg of CpG per mL of ZIF) in both sizes of ZIF (Figure 2A&B) — an important observation given the high cost of CpG. Qualitatively, confocal images of the micro and nano formulations found that the crystals were obviously fluorescent in the FITC channel (Figure 2C). Furthermore, SDS (Figure 2D) and DNase (Figure 2E) washes were employed to remove any surface bound material. From these experiments we note that nZIF seems to adsorb CpG onto the surface more than the larger µZIF, a phenomenon previously detailed by Li et al.58 Given the high concentrations of metal and ligand, we were concerned that hydrolysis of the DNA backbone may occur. Curiously, ZIF growth has never been shown to degrade any biomacromolecules, even with such high concentrations of Lewis acids and alkaline ligands. To the contrary, ZIF shells grow and protect even very delicate systems like protein-embedded liposomes,4 enzymes,59-60 whole yeast,61-62 and bacteria.46,63 To confirm that the CpG was not damaged during encapsulation, the ZIF shells of CpG@µZIF and CpG@nZIF were removed by treatment with 0.5 M EDTA to pull the Zn^{2+} from the coating and recover the DNA. Using a 5% agarose gel stained with ethidium bromide,
we found that the CpG was unaltered (Figure 2F). After confirming the CpG was properly encapsulated in the ZIF-8, we sought to test the ability of ZIF to protect CpG for nuclease degradation. We subjected both CpG@µZIF and CpG@nZIF, as well as CpG controls, to DNase I digestion. After incubation with DNase I for 10 mins at 37 ºC, the CpG@ZIFs samples were exfoliated using 0.5 M EDTA to remove the ZIF shell. The recovered CpG was run on a 5% agarose gel and visualized with ethidium bromide (Figure 2F). It was found that DNase I degraded the unencapsulated CpG whereas encapsulated CpG and PS CpG remained intact. This confirms that ZIF successfully protects CpG for nucleases. Furthermore, we tested CpG adsorbed onto the surface of ZIF (CpG+ZIF) to confirm that the nuclease protection was truly due to encapsulation of the CpG within the ZIF (Figure 2F). Mere surface adsorption did not provide the same protection as encapsulation with complete degradation of the CpG observed following treatment of CpG+ZIF with DNase I. In addition, it was noted that CpG was adsorbed to the surface of nZIF more strongly than µZIF as made evident by the reduced electrophoretic mobility of the CpG, which corroborates our earlier findings.
**Figure 2.** Characterization of CpG encapsulated in ZIF-8. A) Encapsulation efficiency of CpG in ZIF-8 as measured by fluorescence of the supernatant (n=3) ($\lambda_{\text{ex}} = 495$ nm; $\lambda_{\text{em}} = 520$ nm). B) Representative fluorescence spectra of the supernatant used to measure the encapsulation efficiency ($\lambda_{\text{ex}} = 495$ nm). C) Confocal images of FITC-labeled CpG@µZIF (top: scale bar = 10 µm) and CpG@nZIF (bottom: scale bar = 20 µm). D) Quantification of surface adsorbed CpG via a SDS wash and fluorescence measurement of the resulting supernatant (n=3) ($\lambda_{\text{ex}} = 495$ nm; $\lambda_{\text{em}} = 520$ nm). E) Quantification of surface adsorbed CpG via a DNase wash and fluorescence measurement of the resulting supernatant (n=3) ($\lambda_{\text{ex}} = 495$ nm; $\lambda_{\text{em}} = 520$ nm). F) 5% agarose gel characterizing the intactness of CpG before and after DNase I digestion to demonstrate the nuclease protection afforded by ZIF encapsulation.

With our nuclease resistant formulations of CpG, we then moved *in vitro*. First, we confirmed the biocompatibility of both formulations using an LDH cytotoxicity assay and RAW 264.7 murine macrophages (*Figure 3A*) where both formulations were found to be nontoxic after a 4 h incubation at the CpG concentrations we needed to use to induce B-cell maturation (3.3 µg/mL). We then moved forward with cellular assays using splenocytes prepared as a single cell suspension from spleens of naïve BALB/c mice. Splenocytes are a mixture of T-cells, B-cells, monocytes, granulocytes, dendritic cells, natural killer cells, and macrophages and are commonly used for *in vitro* immune stimulation experiments. Using FITC-labeled CpG, we were able to quantify the uptake of CpG@µZIF and CpG@nZIF by B-cells using flow cytometry. After incubating the CpG@ZIFs with splenocytes for 4 h, the cells were washed 3× with a low pH buffer to dissolve any surface ZIF.$^{46,64-65}$ This ensured that the uptake observed indicated the degree of internalization of the particles. The cells were then stained with Alexa Fluor® 700 antimouse CD19 antibody to identify B-cells before being analyzed by flow. From these results, we
found that both CpG@ZIF formulations were able to improve the uptake of CpG (Figure 3B&C). We attribute this to the improved in vitro stability as well as the shielding of the strong negative charge of the DNA by the positively charged carrier. Furthermore, we found that the nano-sized formulation, CpG@nZIF, was taken up more efficiently as compared with the larger CpG@µZIF, following literature examples that nanoparticles are more optimized for cellular uptake. Following uptake by endocytosis, the ZIF is degraded by the acidic pH of the lysosome and releases the CpG cargo to activate B cells. To test this, we incubated CpG@µZIF and CpG@nZIF with splenocytes for 48 h, washed the cells with a low pH buffer, and subsequently stained the cells with three fluorescently-labeled antibodies that allow us to differentiate between naïve B-cells and activated B-cells — Alexa Fluor® 700 anti-mouse CD19 antibody, Alexa Fluor® 647 anti-mouse CD80 antibody, and PE anti-mouse CD86 antibody. In this study we employed PS CpG as a positive control and PS GpC, an antisense complement to PS CpG, as a negative control. Using flow cytometry, we were able to quantify B-cell activation where we found that both CpG@µZIF and CpG@nZIF were able to improve B-cell activation, even matching the performance of the “gold standard” PS CpG (Figure 3D&E). Curiously, despite the significantly enhanced uptake of the CpG@nZIF as compared to CpG@µZIF, there was no significant difference in B-cell activation in these two formulations.
Figure 3. Evaluation of micro and nano CpG@ZIF in vitro. A) LDH cytotoxicity assay quantifying the biocompatibility of CpG@µZIF and CpG@nZIF with RAW 264.7 murine macrophages after 4 h (n=3). B) Uptake of FITC-labeled CpG@µZIF and CpG@nZIF by CD19⁺ B-cells after 4 h incubation as measured by flow cytometry (n=3). C) Representative histogram of the uptake of FITC-labeled CpG, CpG@µZIF, and CpG@nZIF in CD19⁺ B-cells. D) Percent of activated B-cells (CD19⁺ CD80⁺ CD86⁺) after 48 h stimulation with CpG@µZIF and CpG@nZIF as measured by flow cytometry (n=3). E) Representative flow plots of B-cell activation by CpGs and CpG@ZIFs. Statistical significance was calculated by ordinary one-way ANOVA with Tukey’s multiple comparison test (*p < 0.05, **p < 0.01, ***p < 0.0005, ****p < 0.0001; ns = not significant (p > 0.05)).

CONCLUSIONS

In this work, we demonstrate how the zinc-based MOF, ZIF-8, can be used to encapsulate the ssDNA immunoadjuvant CpG. By tuning the metal-to-ligand ratios, we were able to synthesize both micro and nano sizes of the encapsulated formulation. Encapsulation of CpG within ZIF-8...
was shown to stabilize the phosphodiester nucleic acid by protecting it from nuclease degradation. Furthermore, encapsulation of the negatively charged biomacromolecule in the positively charged nanocarrier, ZIF-8, improved cellular uptake of the CpG in B-cells with nano significantly outperforming micro. Together these improvements have demonstrated that ZIF encapsulation has the potential to enhance the function of CpG in adjuvanting an immune response through the activation of B-cells to a comparable degree to the state-of-the-art PS CpG. From this work we hope to shed light on the prospect of using MOFs for the stabilization of phosphodiester DNAs.

AUTHOR INFORMATION

Corresponding Author

Jeremiah J. Gassensmith - Department of Chemistry and Biochemistry, The University of Texas at Dallas, 800 W. Campbell Road, Richardson, Texas 75080, United States; Department of Biomedical Engineering, The University of Texas at Dallas, 800 W. Campbell Road, Richardson, Texas 75080, United States; http://orcid.org/0000-0001-6400-8106; Email: gassensmith@utdallas.edu; Web: www.gassensmithlab.com

Author Contributions

O.R.B. optimized the synthesis of CpG@ZIFs and executed SEM, gel electrophoresis, and all in vitro studies. F. C. H. performed DLS and ζ potential characterizations. Y. W. performed PXRD characterizations. S. D. D. performed BET nitrogen isotherm experiments under the supervision of R. A. S.. R. E. performed confocal fluorescence microscopy, fluorimetry experiments, and aided in all in vitro studies. A. S. also performed fluorimetry experiments. A. R. aided in gel electrophoresis characterizations. O. R. B. and J. J. G. composed the manuscript. J. J. G.
conceived the project. All authors have read and given their approval to the final version of the manuscript.

Funding Sources

J.J.G. acknowledges National Science Foundation (Grants CAREER DMR-1654405 and DMR-2003534) and the Welch Foundation (Grant AT-1989-20190330).

Notes

The authors declare no competing interests.

REFERENCES


